GYRE Amends 8-K for Oct 30 Asset Acquisition/Disposition
Ticker: GYRE · Form: 8-K/A · Filed: Jan 12, 2024 · CIK: 1124105
| Field | Detail |
|---|---|
| Company | Gyre Therapeutics, Inc. (GYRE) |
| Form Type | 8-K/A |
| Filed Date | Jan 12, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: amendment, acquisition, asset-disposition, financial-statements
TL;DR
**GYRE just amended an old 8-K about an asset deal; check for updated financial details!**
AI Summary
Gyre Therapeutics, Inc. filed an 8-K/A on January 12, 2024, to amend its previous 8-K filing from October 30, 2023. This amendment, labeled as Amendment No. 1, specifically addresses the 'Completion of Acquisition or Disposition of Assets' and 'Financial Statements and Exhibits' sections. While the filing doesn't detail the acquisition itself, it signals that the company is providing updated or additional information regarding a significant asset transaction that occurred on October 30, 2023. This matters to investors because it indicates a material change in the company's asset structure, which could impact future financial performance and valuation, and they should look for the details of the acquisition in the original or subsequent filings.
Why It Matters
This filing indicates Gyre Therapeutics is providing updated information about a significant asset transaction, which could materially alter its financial health and future prospects. Investors need to understand the specifics of this acquisition or disposition to assess the company's strategic direction and potential impact on its stock.
Risk Assessment
Risk Level: medium — The filing itself is an amendment, not the original event, but it pertains to a significant asset transaction, the details of which are crucial for assessing company risk and opportunity.
Analyst Insight
Investors should locate the original 8-K from October 30, 2023, and this 8-K/A to understand the full details of the asset acquisition or disposition, including any updated financial statements, to assess the impact on Gyre Therapeutics' valuation and future prospects.
Key Players & Entities
- Gyre Therapeutics, Inc. (company) — the registrant filing the 8-K/A
- October 30, 2023 (date) — date of the earliest event reported in the original 8-K
- January 12, 2024 (date) — date the 8-K/A was filed
- 000-51173 (other) — Commission File Number for Gyre Therapeutics, Inc.
- Delaware (other) — State of incorporation for Gyre Therapeutics, Inc.
FAQ
What is the purpose of this 8-K/A filing by Gyre Therapeutics, Inc.?
This 8-K/A (Amendment No. 1) is filed by Gyre Therapeutics, Inc. to amend its previous Current Report on Form 8-K, specifically concerning 'Completion of Acquisition or Disposition of Assets' and 'Financial Statements and Exhibits' related to an event that occurred on October 30, 2023.
When was the original event reported in the 8-K/A?
The earliest event reported in the original 8-K, which this 8-K/A amends, occurred on October 30, 2023.
What specific items are being amended in the original 8-K?
The 8-K/A amends Item 2.01, 'Completion of Acquisition or Disposition of Assets,' and Item 9.01, 'Financial Statements and Exhibits,' of the original 8-K filing.
What is the trading symbol and exchange for Gyre Therapeutics, Inc.?
Gyre Therapeutics, Inc. trades under the symbol GYRE on NASDAQ, as indicated by the 'Securities registered pursuant to Section 12(b) of the Act' section.
What was Gyre Therapeutics, Inc.'s former company name?
According to the filing, Gyre Therapeutics, Inc. was formerly known as Catalyst Biosciences, Inc., with a name change date of 20150820, and even earlier as Targacept Inc, with a name change date of 20000919.
Filing Stats: 1,011 words · 4 min read · ~3 pages · Grade level 11.8 · Accepted 2024-01-12 16:01:35
Filing Documents
- ef20018550_8ka.htm (8-K/A) — 37KB
- ef20018550_ex99-1.htm (EX-99.1) — 1207KB
- ef20018550_ex99-2.htm (EX-99.2) — 609KB
- 0001140361-24-002118.txt ( ) — 2116KB
- gyre-20231030.xsd (EX-101.SCH) — 4KB
- gyre-20231030_lab.xml (EX-101.LAB) — 22KB
- gyre-20231030_pre.xml (EX-101.PRE) — 16KB
- ef20018550_8ka_htm.xml (XML) — 4KB
01
Item 2.01. Results of Operations and Financial Condition. This Amendment No. 1 includes (i) the financial statements of BC and related notes as of and for the years ended December 31, 2022 and 2021 and the unaudited financial statements of BC as of and for the nine months ended September 30, 2023, and (ii) the unaudited pro forma condensed combined balance sheet of Catalyst and BC as of September 30, 2023 and the unaudited pro forma condensed combined statement of operations of Catalyst and BC for the nine months ended September 30, 2023 and the year ended December 31, 2022. The information set forth under Item 9.01 of this Current Report on Form 8-K is incorporated herein by reference.
01
Item 9.01 Exhibits. (a) Financial Statements of Business Acquired The financial statements of BC and related notes as of and for the years ended December 31, 2022 and 2021 and the unaudited financial statements of BC as of and for the nine months ended September 30, 2023 and for the periods then ended and related notes thereto are attached as Exhibit 99.1 and are incorporated herein by reference. (b) Pro Forma Financial Information The unaudited pro forma condensed combined balance sheet of Catalyst and BC as of September 30, 2023 and the unaudited pro forma condensed combined statement of operations of Catalyst and BC for the nine months ended September 30, 2023 and the year ended December 31, 2022 and the related notes thereto are attached as Exhibit 99.2 and are incorporated herein by reference. (d) Exhibits EXHIBIT INDEX Exhibit Number Description 99.1 Unaudited financial statements of BC and related notes as of and for the nine months ended September 30, 2023 and financial statements of BC and related notes as of and for the years ended December 31, 2022 and 2021. 99.2 Unaudited pro forma condensed combined balance sheet of Catalyst and BC as of September 30, 2023 and the unaudited pro forma condensed combined statement of operations of Catalyst and BC for the nine months ended September 30, 2023 and the year ended December 31, 2022. 104 Cover Page Interactive Data File (formatted as Inline XBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Gyre Therapeutics, Inc. Date: January 12, 2024 By: /s/ Ruoyu Chen Name: Ruoyu Chen Title: Chief Financial Officer